iCAD Inc. - ICAD Operating Margin

iCAD Corp - graphic logo of issuer ICAD

iCAD, Inc. (ICAD) is transitioning to cloud subscriptions to stabilize revenue while controlling the timing of corporate deals. Physician efficiency is increasing due to the precision of AI algorithms in the early detection of breast tumors. A technological alliance with X-ray equipment manufacturers is transforming diagnostics. The core business margin reflects capital dynamics, where the value -30.50 indicates the current amount of operating profit before taxes and interest.

iCAD Inc. (ICAD): Return on Sales by Operating Profit from 07/04/2022 to 08/02/2025

ICAD (iCAD Inc.): analytical breakdowns and indicator data

- stock quotes and analyst forecast:
Initial company analysis:iCAD Inc., ICAD
Brand item of iCAD

The active development of the iCAD, Inc. (ICAD) R&D pipeline in AI-driven oncology diagnostics requires significant expenditure, which directly impacts operational efficiency. By analyzing operating margin metrics, investors assess the share of profit from the core business before interest and taxes, where a stable chart trajectory confirms the company's ability to convert technological updates into actual operating income.

Analysis of competing companies

Operating Profitability BeiGene Ltd|Halozyme Therapeutics - Operating Profit Margin|Operating Sales Margin RVMD (Revolution Medicines Corp)|Operating Profit Ratio AAPG|Operating Profitability CG Oncology Therapeutics CGON|Operating Profit Rate URGN|BCAX: Operating Sales Margin|PSNL: Operating Profitability|Erasca (ERAS) - Operating Profitability|DCTH - Profitability of Operations|YMAB (Y-mAbs Corp) - Operating Margin|Operating Sales Margin Aura Biosciences (AURA)|Operating Profitability Candel Therapeutics Inc. (CADL)|Operating Sales Margin Accuray, Inc. ARAY|Operating Profitability sellaslifesciences.com SLS|Operating Profit Rate ACTU|CTOR - Operating Profitability|Profitability of Operations tuhurabio.com HURA|Protara Therapeutics, Inc. (TARA) - Operating Profitability|FATE: Operating Profit Ratio|WHWK (Aadi Bioscience, Inc.) - Operating Margin|TCRX (TScan Therapeutics) - Operating Profit Ratio|Operating Profitability Champions Oncology (CSBR)|Profitability of Operations XBiotech USA|Operating Profitability CEL-SCI CVM|OS Therapies, Inc. (OSTX) - Operating Return on Sales|RADX - Operating Profitability|ARTV - Operating Margin|Adlai Nortye Ltd (ANL) - Operating Profitability|Veru Pharma - Operating Profit Rate|Operating Profitability Tempest Therapeutics Corp|Return on Sales by Operating Profit XLO (Xilio Therapeutics, Inc.)|Operating Margin RENB|MURA (Mural Oncology) - Operating Profit Rate|Operating Margin KAPA (Kairos Pharma Ltd)|OKUR: Return on Sales by Operating Profit|GDTC: Operating Sales Margin|CRIS - Operating Margin|APLM: Operating Margin|Operating Return on Sales tharimmune.com (THAR)|ADVB (Advanced Biomed Corp) - Operating Margin|Operating Margin Genprex Inc.|Operating Margin CLDI|Operating Sales Margin Sunshine Biopharma, Inc. SBFM|Operating Margin XBIO (Xenetic Biosciences)|Operating Profit Rate SLRX|PPBT - Operating Profitability|AONC (aoncology.com) - Return on Sales by Operating Profit|BGNE: Operating Margin|Checkpoint Therapeutics Inc (CKPT) - Operating Margin|ELEV (Elevation Oncology Inc.) - Operating Margin|IKNA: Operating Profit Rate|Operating Profitability Notable Labs (NTBL)|VIRX (Viracta Therapeutics, Inc.) - Operating Profit Rate|Operating Profitability MorphoSys Corporation MOR|NAYA: Return on Sales by Operating Profit|Ascentage Pharma Group International - Operating Margin